Contineum CEO exercises options, sells 2,500 shares

Contineum Therapeutics CEO Carmine N. Stengone reported an option exercise and share sale in Class A Common Stock.

Accepted by SEC EDGAR 07/08/2026 - 06:49 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Contineum Therapeutics CEO Carmine N. Stengone reported an option exercise and share sale in Class A Common Stock. He exercised stock options for 2,500 shares at $1.01 per share and sold 2,500 shares at $16.00 per share on July 8, 2026. These trades were executed under a Rule 10b5-1 trading plan adopted on September 23, 2025. After the transactions, he holds 17,217 shares directly and 279,430 stock options expiring on February 24, 2030.

Insider Trade Summary 10b5-1

Exercise and Sale: 2,500 shares ($37K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Stengone Carmine N.

Role CEO and President

Sold 2,500 shs ($40K)

Approx. gross sale proceeds $40K

Approx. exercise cost $3K

Approx. pre-tax spread $37K

Share of Position Sold 12.7%

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	2,500	$0.00	$0.00
Exercise	Class A Common Stock	2,500	$1.01	$3K
Sale	Class A Common Stock	2,500	$16.00	$40K

Holdings After Transaction: Stock Option (right to buy) — 279,430 contracts (Direct); Class A Common Stock — 17,217 shares (Direct)

Holdings Before and After: Stock Option (right to buy), 281,930 to 279,430 contracts (Direct); Class A Common Stock, 17,217 to 17,217 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
2. F2. Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.

Key Figures

Shares sold: 2,500 shares Sale price: $16.00/share Options exercised: 2,500 options +5 more

8 metrics

Shares sold 2,500 shares Class A Common Stock sold at $16.00 on July 8, 2026

Sale price $16.00/share Open-market sale of 2,500 Class A shares

Options exercised 2,500 options Exercised into Class A shares at $1.01 on July 8, 2026

Option exercise price $1.01/share Stock Option (right to buy) under 2012 Equity Incentive Plan

Shares held after 17,217 shares Direct Class A Common holdings following transactions

Options remaining 279,430 options Stock options outstanding after exercise, expiring February 24, 2030

Net share change -2,500 shares Net-sell direction from transaction summary

10b5-1 plan adoption date September 23, 2025 Date CEO adopted trading plan used for these transactions

Key Terms

Rule 10b5-1 trading plan, Stock Option (right to buy), Equity Incentive Plan, Class A Common Stock, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Equity Incentive Plan financial

"Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan")."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Class A Common Stock financial

"security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

derivative exercise/conversion financial

"transaction_action: derivative exercise/conversion"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CTNM CEO Carmine Stengone report?

CTNM CEO Carmine N. Stengone reported exercising stock options for 2,500 Class A shares and selling 2,500 shares. Both transactions occurred on July 8, 2026 and were disclosed in a Form 4 insider trading report.

At what prices did the CTNM CEO exercise and sell shares?

Carmine N. Stengone exercised stock options at $1.01 per share and sold 2,500 Class A Common shares at $16.00 per share. These transactions reflect an exercise-and-sell pattern typical for monetizing vested equity compensation.

How many Contineum Therapeutics shares does the CEO hold after this Form 4?

Following the reported transactions, Carmine N. Stengone directly holds 17,217 shares of Contineum Therapeutics Class A Common Stock. He also retains 279,430 stock options, providing additional potential equity exposure if exercised before expiration.

Were the CTNM CEO’s trades made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025. Such plans pre-schedule trades, helping separate routine liquidity events from discretionary market-timing decisions.

What stock options are involved in the CTNM CEO’s Form 4 filing?

The filing shows exercise of 2,500 stock options with a $1.01 exercise price, granted under the company’s 2012 Equity Incentive Plan. After this exercise, 279,430 options remain outstanding and are fully vested, expiring on February 24, 2030.

What is the net effect of the CTNM CEO’s Form 4 on share count?

The transaction summary indicates a net sale of 2,500 non-derivative shares. The CEO exercised 2,500 options to acquire shares, then sold 2,500 shares, ending with 17,217 directly held shares and unchanged total option grants aside from the exercised portion.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stengone Carmine N.

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/08/2026		M(1)		2,500	A	$1.01	19,717	D
Class A Common Stock	07/08/2026		S(1)		2,500	D	$16	17,217	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.01	07/08/2026		M(1)			2,500	(2)	02/24/2030	Class A Common Stock	2,500	$0	279,430	D

Explanation of Responses:

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

2. Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.

Remarks:

	/s/ Peter Slover, Attorney-in-Fact	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)